• HCA Healthcare highlighted a New England Journal of Medicine study, with results already published, on a CRISPR-based therapy in children with inherited blood disorders.
• The trials showed the treatment helped children avoid major disease complications, supporting the case for earlier intervention versus waiting until adolescence.
• The therapy is already cleared in the US for patients 12 and older, positioning the pediatric data as a potential expansion pathway if regulators accept it.
• HCA is using the findings to support a broader rollout of gene-editing care through its transplant and cellular therapy programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HCA Healthcare Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606290830BIZWIRE_USPR_____20260629_BW348492) on June 29, 2026, and is solely responsible for the information contained therein.